Literature DB >> 20438312

Two-port access staging laparoscopy for gynecologic cancers: a pilot study.

Jiheum Paek1, Eun Ji Nam, Yong Wook Jung, San Hui Lee, Jae Hoon Kim, Young Tae Kim, Sang Wun Kim.   

Abstract

BACKGROUND: The aims of this work were to introduce a two-port access (TPA) staging laparoscopy in gynecologic cancers and evaluate the feasibility and surgical outcomes of this operation.
MATERIALS AND METHODS: We performed 12 cases of TPA staging laparoscopy. The TPA system consisted of a single multichannel port at the umbilicus and an ancillary 5-mm port in the suprapubic area. Patient status was estimated in terms of operative morbidity and surgical outcomes.
RESULTS: All operations were completed laparoscopically, with no conversions to conventional laparoscopy or laparotomy. Procedures included endometrial cancer staging (n = 6), ovarian cancer staging (n = 3), 2 cases of type III radical hysterectomy, and 1 type II radical hysterectomy. Median patient age and body mass index were 48 years and 20.4 kg/m(2), respectively. Median operation duration was 241 minutes (range, 188-360). Median estimated blood loss was 175 mL. Median number of lymph nodes obtained was 30 (range, 14-49). Median postoperative hospital stay was 8 days. There were no perioperative complications.
CONCLUSIONS: TPA staging laparoscopy, using the single multichannel port system, could be a feasible procedure in selected gynecologic cancer patients, with only minimal skin incisions. Prospective, randomized trials will permit the evaluation of potential benefits of this minimally invasive surgical technique.

Entities:  

Mesh:

Year:  2010        PMID: 20438312     DOI: 10.1089/lap.2009.0456

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  1 in total

1.  Single-port access laparoscopic staging operation for a borderline ovarian tumor.

Authors:  Aera Yoon; Tae-Joong Kim; Woo Seok Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  J Gynecol Oncol       Date:  2011-06-30       Impact factor: 4.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.